Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease

Alzheimer's and Dementia: Translational Research and Clinical Interventions

Volumn 3, Issue 1, 2017, Pages 1-9

  Rinne, Juha O ^a,b   Wesnes, Keith ^c,d,e   Cummings, Jeffrey L ^f   Hakulinen, Pasi ^g   Hallikainen, Merja ^h   Hänninen, Jutta ^g   Murphy, Michael ⁱ   Riordan, Henry ⁱ   Scheinin, Mika ^b,j   Soininen, Hilkka ^h   Rouru, Juha ^g  

^a TURKU PET CENTRE   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c Bracket Global   (United Kingdom)

^d NORTHUMBRIA UNIVERSITY   (United Kingdom)

^e SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^f CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH   (United States)

^g ORION CORPORATION   (Finland)

^h UNIVERSITY OF EASTERN FINLAND   (Finland)

ⁱ Worldwide Clinical Trials   (United States)

^j UNIVERSITY OF TURKU   (Finland)

more..

Author keywords

Alpha 2C adrenoceptor antagonist; Alzheimer's disease; Behavioral and psychological symptoms of dementia; Cognition; Memory; Neuropsychiatric symptoms; ORM 12741; Randomized trials

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; DONEPEZIL; GALANTAMINE; LIVER ENZYME; ORM 12741; PLACEBO; RIVASTIGMINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CAREGIVER DISTRESS SCORE; CHOLESTASIS; COGNITION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISODIC MEMORY; FEMALE; HEADACHE; HUMAN; IRRITABILITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NAUSEA; NEUROPSYCHIATRIC INVENTORY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF EPISODIC MEMORY SCORE; QUALITY OF WORKING MEMORY COMPOSITE SCORE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SYMPTOMATOLOGY; URINARY TRACT INFECTION; VOMITING;

EID: 85012247251     PISSN: None     EISSN: 23528737     Source Type: Journal    
DOI: 10.1016/j.trci.2016.11.004     Document Type: Article

References (32)

1. [1] Ehret, M.J., Chamberlin, K.W., Current practices in the treatment of Alzheimer disease: where is the evidence after the phase III trials?. Clin Ther 37 (2015), 1604–1616.
2. [2] Gauthier, S., Cummings, J., Ballard, C., Brodaty, H., Grossberg, G., Robert, P., et al. Management of behavioral problems in Alzheimer's disease. Int Psychogeriatr 22 (2010), 346–372.
3. [3] Kales, H.C., Gitlin, L.N., Lyketsos, C.G., Assessment and management of behavioral and psychological symptoms of dementia. BMJ, 350, 2015, h369.
4. [4] Cummings, J.L., Morstorf, T., Zhong, K., Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther, 6, 2014, 37.
5. [5] MacDonald, E., Kobilka, B.K., Scheinin, M., Gene targeting–homing in on alpha 2-adrenoceptor-subtype function. Trends Pharmacol Sci 18 (1997), 211–219.
6. [6] Scheinin, M., Sallinen, J., Haapalinna, A., Evaluation of the alpha2C-adrenoceptor as a neuropsychiatric drug target studies in transgenic mouse models. Life Sci 68 (2001), 2277–2285.
7. [7] Sallinen, J., Hoglund, I., Engstrom, M., Lehtimaki, J., Virtanen, R., Sirvio, J., et al. Pharmacological characterization and CNS effects of a novel highly selective alpha2C-adrenoceptor antagonist JP-1302. Br J Pharmacol 150 (2007), 391–402.
8. [8] Sallinen, J., Holappa, J., Koivisto, A., Kuokkanen, K., Chapman, H., Lehtimaki, J., et al. Pharmacological characterisation of a structurally novel alpha2C-adrenoceptor antagonist ORM-10921 and its effects in neuropsychiatric models. Basic Clin Pharmacol Toxicol 113 (2013), 239–249.
9. [9] Lehto, J., Virta, J.R., Oikonen, V., Roivainen, A., Luoto, P., Arponen, E., et al. Test-retest reliability of (11)C-ORM-13070 in PET imaging of alpha2C-adrenoceptors in vivo in the human brain. Eur J Nucl Med Mol Imaging 42 (2015), 120–127.
10. [10] Luoto, P., Suilamo, S., Oikonen, V., Arponen, E., Helin, S., Herttuainen, J., et al. (11)C-ORM-13070, a novel PET ligand for brain alpha(2)C-adrenoceptors: radiometabolism, plasma pharmacokinetics, whole-body distribution and radiation dosimetry in healthy men. Eur J Nucl Med Mol Imaging 41 (2014), 1947–1956.
11. 11C]ORM-13070 as a PET tracer for alpha2c-adrenoceptors in the human brain. Synapse 69 (2015), 172–181.
12. [12] McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984), 939–944.
13. [13] American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorder, 4th ed, text revision (DSM-IV-TR). 2000, American Psychiatric Association, Washington, DC.
14. [14] Cummings, J.L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D.A., Gornbein, J., The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44 (1994), 2308–2314.
15. [15] Simpson, P., Surmon, D., Wesnes, K., Wilcock, G., The Cognitive Drug Research computerised assessment system for demented patients: a validation study. Int J Geriatr Psychiatry 6 (1991), 95–102.
16. [16] Wesnes, K.A., Ward, T., McGinty, A., Petrini, O., The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology (Berl) 152 (2000), 353–361.
17. [17] Galvin, J.E., Cornblatt, B., Newhouse, P., Ancoli-Israel, S., Wesnes, K., Williamson, D., et al. Effects of galantamine on measures of attention: results from 2 clinical trials in Alzheimer disease patients with comparisons to donepezil. Alzheimer Dis Assoc Disord 22 (2008), 30–38.
18. [18] Wesnes, K.A., McKeith, I., Edgar, C., Emre, M., Lane, R., Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 65 (2005), 1654–1656.
19. [19] Wesnes, K.A., McKeith, I.G., Ferrara, R., Emre, M., Del Ser, T., Spano, P.F., et al. Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord 13 (2002), 183–192.
20. [20] Loonstra, A.S., Tarlow, A.R., Sellers, A.H., COWAT metanorms across age, education, and gender. Appl Neuropsychol 8 (2001), 161–166.
21. [21] Weintraub, S., Salmon, D., Mercaldo, N., Ferris, S., Graff-Radford, N.R., Chui, H., et al. The Alzheimer's Disease Centers’ Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord 23 (2009), 91–101.
22. [22] Alexopoulos, G.S., Abrams, R.C., Young, R.C., Shamoian, C.A., Cornell scale for depression in dementia. Biol Psychiatry 23 (1988), 271–284.
23. [23] Winblad, B., Poritis, N., Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 14 (1999), 135–146.
24. [24] Broadbent, D.E., Cooper, P.F., FitzGerald, P., Parkes, K.R., The Cognitive Failures Questionnaire (CFQ) and its correlates. Br J Clin Psychol 21:Pt 1 (1982), 1–16.
25. [25] Cohen, J., Chapter 8: F tests on means in the analysis of variance and co-variance. Statistical power analysis for the behavioral sciences, 2nd ed., 1988, Lawrence Erlbaum Associates, Hillsdale, NJ.
26. [26] Wesnes, K.A., Harrison, J., Edgar, C., Pincock, C., The sensitivity and reliability of the Cognitive Drug Research computerised cognitive assessment system to disease progression and treatment response in Alzheimer's disease. Int Psychogeriatr, 17, 2005, 154.
27. [27] Peters, M.E., Schwartz, S., Han, D., Rabins, P.V., Steinberg, M., Tschanz, J.T., et al. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: the Cache County Dementia Progression Study. Am J Psychiatry 172 (2015), 460–465.
28. [28] Rockwood, K., Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry 75 (2004), 677–685.
29. [29] Corey-Bloom, J., Anand, R., Veach, J., A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1 (1998), 55–65.
30. [30] Burns, A., Rossor, M., Hecker, J., Gauthier, S., Petit, H., Moller, H.J., et al. The effects of donepezil in Alzheimer's disease—results from a multinational trial. Dement Geriatr Cogn Disord 10 (1999), 237–244.
31. [31] Rogers, S.L., Farlow, M.R., Doody, R.S., Mohs, R., Friedhoff, L.T., A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 50 (1998), 136–145.
32. [32] Wesnes, K., Edgar, C., Andreasen, N., Annas, P., Basun, H., Lannfelt, L., et al. Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease. Acta Neurol Scand 122 (2010), 270–277.